HARROW HEALTH INC HROW 深 滬
等待開盤 09-30 09:30:00 美东时间
48.40
+1.300
+2.76%
華盛通- 最 高50.39
- 今 開49.54
- 成交量 124.37万股
- 最 低 47.32
- 昨 收 47.10
- 總市值 17.91亿
- 52周最高 59.23
- 市盈率 靜 --
- 換手率 3.36%
- 52周最低 20.85
- 委 比 95.40%
- 總股本 3700.21万
- 歷史最高 59.23
- 量 比 1.51
- 振 幅 6.52%
- 歷史最低 3.33
- 每 手 1
- 風險率 13.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多诺华出售眼科给康哲即将揭盅？跨国公司“战略调整潮”可能刚刚开始
（来源：医趋势） 近日，市场再次传出消息，诺华中国的眼科业务可能整体出售给中国康哲药业。 回溯今年8月，相关传闻已现端倪——当时便有消息称，诺华中国的眼前节产...
09-29 10:52
Harrow Health Acquires Melt Pharmaceuticals for Expansion
Harrow Health ( ($HROW) ) has issued an update. On September 26, 2025, Harrow a...
09-26 19:28
Harrow to buy Melt Pharmaceuticals
Harrow (NASDAQ:HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, a...
09-26 19:10
Harrow To Acquire Melt Pharma, Advancing Sublingual Sedation Therapy MELT-300 Toward 2027 NDA After Positive Phase 3 Results
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a
09-26 19:03
Harrow Launches Harrow Access for All (HAFA)
Harrow launched its HAFA program to expand access to its ophthalmic medications, building on the successful VAFA initiative. HAFA offers affordable pricing, with out-of-pocket costs capped at $59, and streamlines the prescribing process through the HarrowAccess.com portal. The program will be implemented in three phases, starting late 2025, covering all products by 2027.
09-25 20:05
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Demystifying Harrow: Insights From 5 Analyst Reviews
In the latest quarter, 5 analysts provided ratings for Harrow (NASDAQ:HROW), sh...
09-24 04:01
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $64
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $54 to $64.
09-23 21:51
Harrow Announces Agenda and Speakers for Investor & Analyst Day
Harrow, a leading provider of ophthalmic disease management solutions, will host its Investor & Analyst Day on September 26, 2025, in New York. The event, webcast live, will feature presentations from Harrow’s leadership team, renowned physicians, and key opinion leaders on the company’s business, pipeline, and long-term vision. Topics include financial updates, product overviews, and expert perspectives on treatments like dry eye disease, retina...
09-15 11:00
Harrow launches $250M debt offering
Harrow (NASDAQ:HROW) has commenced a private offering of $250.0 million aggregate principal amount of senior unsecured notes due 2030. The company plans to use proceeds from the offering to fully repa...
09-08 20:26
